OpenLegislation

Regulation 217B Amendment of regulation 306 (decision about compatibility)F1I1

In regulation 306—

(a)

in paragraph (2), after “Chapter 2” insert—

“and specify whether the incompatibility is insofar as the advertisement is for publication—

(a)

in Great Britain;

(b)

in Northern Ireland; or

(c)

in both Great Britain and Northern Ireland”;

(b)

in paragraph (4)—

(i)

in sub-paragraph (a), after “Chapter 2” insert—

“insofar as the advertisement is for publication—

(i)

in Great Britain;

(ii)

in Northern Ireland; or

(iii)

in both Great Britain and Northern Ireland”;

(ii)

after “no longer applies” insert “in Great Britain, Northern Ireland, or both Great Britain and Northern Ireland (as appropriate)”;

(c)

in paragraph (5), after “Chapter 2” insert—

“insofar as the advertisement is for publication—

(a)

in Great Britain;

(b)

in Northern Ireland; or

(c)

in both Great Britain and Northern Ireland”;

(d)

in paragraph (7)(b), after “no longer applies” insert—

  • “,

and where that original notice related to both Great Britain and Northern Ireland, the new notice may be expressed to apply in relation to either of or both Great Britain and Northern Ireland”;

(e)

in paragraph (8), after “the advertisement” insert—

“—

(a)

in Great Britain;

(b)

in Northern Ireland; or

(c)

in both Great Britain and Northern Ireland”.

Annotations

Textual amendments

F1

Regs. 217A-217D inserted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 177

Commencement

I1

Reg. 217B in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1